{
  "docId": "019de076-1fa8-714d-830b-c99557c4e3f8",
  "docSlug": "94eecf41575130a8334503229ea21cd4",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 26,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a column-based layout with icons and supporting text to present company strengths.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-1fa8-714d-830b-c99557c4e3f8/4",
  "deckHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8",
  "deckJsonHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8.json",
  "deckAnchorHref": "/decks/019de076-1fa8-714d-830b-c99557c4e3f8#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.605,
        "w": 0.824,
        "x": 0.088,
        "y": 0.225
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3cc0a84d-260d-4d1f-99ed-738e6069648d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.824,
        "x": 0.088,
        "y": 0.225
      },
      "kind": "list",
      "text": "Indications with significant unmet medical need & large market opportunities; Team with virology expertise and proven track record; Portfolio of internally discovered assets with distinct MOAs; Lead HBV compound – imdusiran (AB-729) RNAi therapeutic in multiple Phase 2a combination clinical trials; Strong financial position; Patented LNP technology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b188474-261f-4a09-9605-686bf0869f99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.255,
        "w": 0.824,
        "x": 0.088,
        "y": 0.575
      },
      "kind": "paragraph",
      "text": "Focused on developing a functional cure for HBV; Discovered, developed & commercialized multiple drugs; RNAi therapeutic PD-L1 inhibitor; Data shows imdusiran is generally safe and well-tolerated and has shown meaningful suppression of HBsAg while on- or off-treatment; Cash runway into Q1 2026; Receiving licensing royalties arising from Alnylam’s Onpattro® and seeking damages for Moderna & Pfizer/BioNTech COVID-19 vaccine sales",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1053508b-c30b-4473-8d05-c6447dfe38c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.43,
        "x": 0.145,
        "y": 0.938
      },
      "kind": "source-note",
      "text": "MOA: Mechanism of Action | PD-L1: Programmed death-ligand 1 | HBsAg: Hepatitis B surface antigen",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60b22b78-6762-495a-9250-a0dce3c741ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.083,
        "w": 0.394,
        "x": 0.076,
        "y": 0.056
      },
      "kind": "title",
      "text": "Investment Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69ee339c-96dd-4c26-9f5d-a1c387cfc2cb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "c8a613c7-a97d-40f8-a64f-998326295579",
      "evidence": "Focused on developing a functional cure for HBV; Discovered, developed & commercialized multiple drugs; RNAi therapeutic PD-L1 inhibitor; Data shows imdusiran is generally safe and well-tolerated and",
      "confidence": 0.7
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "53c11c2b-ab2e-4e26-801b-93a8f3a9b5bd",
      "evidence": "Indications with significant unmet medical need & large market opportunities; Team with virology expertise and proven track record; Portfolio of internally discovered assets with distinct MOAs;",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}